? March is #AutoimmuneAwarenessMonth! Take a minute to learn about #AutoimmuneHepatitis, a rare disease affecting more than 100,000 Americans and the PORTOLA Trial evaluating #zetomipzomib, our first-in-class selective immunoproteasome inhibitor for those living with #AIH: https://PORTOLAtrial.com/.
Kezar Life Sciences
生物技术研究
South San Francisco，California 5,168 位关注者
Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders
关于我们
We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be applied across a vast array of indications to create victories for patients most in need.
- 网站
-
https://kezarlifesciences.com/
Kezar Life Sciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- South San Francisco，California
- 类型
- 上市公司
- 创立
- 2015
- 领域
- Biotechnology、Autoimmune Disease、Immunology、Oncology、Drug Discovery和Drug Development
地点
-
主要
获取路线
4000 Shoreline Ct
Suite 300
US，California，South San Francisco，94080
Kezar Life Sciences员工
动态
-
As the year draws to a close, we want to wish you a festive holiday season filled with peace, joy and good company.?Sending warm thoughts to you and your loved ones. #HappyHolidays?
-
-
Today, we released our third quarter 2024 financial results along with recent business updates. Learn more in the full news release here: https://lnkd.in/gKMCW8gG
-
-
Tomorrow, Kezar’s CEO,?Chris Kirk,?will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference! ?A webcast of the discussion will be available on our website's “Events & Presentations” section here: https://lnkd.in/eQbXMpBN #HCWainwrightGlobal
-
-
Targeted treatments that are potentially steroid-sparing are on the horizon for #lupusnephritis. Read about it in @FrontIn [https://lnkd.in/d5PDRnze]. #openaccess @kezarbio
-
Today, we announced our participation at the H.C. Wainwright 26th Annual Global Investment Conference in #NewYorkCity next week. Learn more about our upcoming presentation in our latest press release here: https://lnkd.in/gyVPictb #HCWainwrightGlobal
-
-
Today, we released our second quarter 2024 financial results along with recent business updates. Learn more in the full news release here: https://lnkd.in/g27h6C9h
-
-
Today, we released our second quarter 2024 financial results along with recent business updates. Learn more in the full news release here: https://lnkd.in/g27h6C9h
-
-
We are excited to share that our partner, Everest Medicines, has dosed the first patient in China.?Their team continues to integrate seamlessly with ours to drive forward our global Phase 2b clinical trial evaluating zetomipzomib in adults living with LN. https://lnkd.in/gJu83GfZ
-
Zetomipzomib is the only selective immunoproteasome inhibitor being evaluated in clinical trials for lupus nephritis. Learn more about the PALIZADE trial at https://lnkd.in/gtxDfybE. #PALIZADEtrial #zetomipzomib #LupusNephritis
-